TABLE 1.
Description of cohort
| Variable | Levocarnitine prophylaxis | Levocarnitine rescue | No levocarnitine | p‐value | ||||
|---|---|---|---|---|---|---|---|---|
| N | (%) | N | (%) | N | (%) | All Groups | Prophylaxis versus no levocarnitine | |
| Cohort | 29 | (100) | 23 | (100) | 109 | (100) | ||
| Age, years | ||||||||
| 10–14.9 | 8 | (28) | 3 | (13) | 57 | (52) | 0.001 | 0.018 |
| 15.0–39.9 (AYA) | 21 | (72) | 20 | (87) | 52 | (48) | ||
| Median (range) | 17.0 | (12–26.3) | 18.8 | (11.7–35) | 14.7 | (10–27.2) | <0.001 | 0.001 |
| Sex | ||||||||
| Female | 8 | (28) | 6 | (26) | 42 | (39) | 0.349 | 0.276 |
| Male | 21 | (72) | 17 | (74) | 67 | (61) | ||
| Ethnicity | ||||||||
| Not Hispanic/Latinx | 21 | (72) | 13 | (56) | 29 | (27) | <0.001 | <0.001 |
| Hispanic/Latinx | 4 | (14) | 10 | (44) | 70 | (64) | ||
| Unknown | 4 | (14) | 0 | (0) | 10 | (9) | ||
| BMI category a | ||||||||
| Not obese | 6 | (21) | 10 | (43) | 76 | (70) | <0.001 | <0.001 |
| Obese | 23 | (79) | 13 | (57) | 33 | (30) | ||
| BMI percentile | ||||||||
| Median (range) | 98.3 | (18.1–99.8) | 98.8 | (19.3–99.7) | 79.0 | (0.2–99.8) | 0.001 | 0.001 |
| Diagnosis | ||||||||
| B‐ALL | 28 | (97) | 21 | (91) | 89 | (82) | 0.105 | 0.076 |
| T‐ALL | 1 | (3) | 2 | (9) | 20 | (18) | ||
| Presenting WBC b | ||||||||
| <50 K/ul | 17 | (59) | 13 | (56) | 76 | (70) | 0.280 | 0.229 |
| ≥50 K/ul | 12 | (41) | 10 | (44) | 32 | (30) | ||
| FISH/Cytogenetics c | ||||||||
| Neutral | 11 | (39) | 9 | (43) | 37 | (42) | 0.002 | 0.004 |
| Favorable | 1 | (4) | 0 | (0) | 9 | (10) | ||
| Adverse | 16 | (57) | 12 | (57) | 25 | (28) | ||
| Unknown | 0 | (0) | 0 | (0) | 18 | (20) | ||
Abbreviations: ALL, acute lymphoblastic leukemia; BMI, body mass index; FISH, Fluorescence in situ hybridization; WBC, white blood cell count.
a
Obesity categorized using age/sex norms for age 10–20 years and absolute BMI ≥30 for age ≥20 years (absolute BMI not included in median/range).
b
One patient unknown.
c
For B‐ALL patients, classified using Children's Oncology Group biology protocol AALL08B1 (modified to include Ph‐like signatures as adverse prognostic markers).